Eric M. Gordon
Fondatore presso Arixa Pharmaceuticals, Inc.
Profilo
Eric has been a distinguished medicinal chemist, company founder and senior executive since the early 1970s.
He was head of medicinal chemistry at Squibb and Bristol Myers Squibb in Princeton, where he worked for 18 years.
In 1992, he became Vice President of Research and Director of Chemistry at Affymax in Palo Alto, and had that role until the company was sold to Glaxo in 1995.
In 1996, he became scientific co-founder, President and Chief Scientific Officer of Versicor (later Vicuron Pharmaceuticals, which was acquired by Pfizer in 2005).
In 1998 he participated in the early stages of Sunesis Pharmaceuticals (NASDAQ: SNSS) and was Senior Vice President of Research until late 2002.
He is an accepted authority on combinatorial chemistry, medicinal chemistry, and creating drugs through enzyme inhibition.
Eric has authored more than 200 scientific manuscripts and U.S.
patents, and portions of 3 books, including editing a comprehensive book on combinatorial chemistry.
He is the senior author of two manuscripts which during 1994-1996 were the most frequently cited chemistry papers in the world.
He is on the Scientific Advisory Boards of the Cystic Fibrosis Foundation and the Organization for One World Health, as well as several biotechnology companies.
He serves on the Editorial Advisory Board of five scientific journals.
In 1997 he was elected a Fellow of the American Association for the Advancement of Science (AAAS).
He received his Ph.D.
and M.S.
in medicinal chemistry from the University of Wisconsin in Madison and conducted post-doctoral work at Yale University.
He joined Skyline in 2002.
Like John, he is a lifelong Yankee fan, but is old enough to have attended Woodstock, the Beatles concert at Shea Stadium in 1965, and the 1968 Democratic Convention in Chicago.
Posizioni attive di Eric M. Gordon
| Società | Posizione | Inizio |
|---|---|---|
Skyline Management LLC
 Skyline Management LLC Investment ManagersFinance Skyline Management LLC (Skyline Management) is a venture capital firm founded in 1997 by John Gordon Freund. The firm is headquartered in Palo Alto, California. | Investitore di Private Equity | 01/01/2002 |
Arixa Pharmaceuticals, Inc.
 Arixa Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arixa Pharmaceuticals, Inc. engages in the development of oral antibiotics for resistant gram-negative infections. The company was founded by Eric Gordon, John Gordon Freund, and Joaquim Trias in 2016 and is headquartered in Palo Alto, CA. | Fondatore | 01/01/2016 |
Precedenti posizioni note di Eric M. Gordon
| Società | Posizione | Fine |
|---|---|---|
| TETRAPHASE PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 23/10/2012 |
Targanta Therapeutics Corp.
 Targanta Therapeutics Corp. BiotechnologyHealth Technology Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ. | Direttore/Membro del Consiglio | 26/02/2009 |
| VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | 31/12/2001 |
Vicuron Pharmaceuticals LLC
 Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Fondatore | 31/12/1997 |
Affymax Research Institute
 Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | Corporate Officer/Principal | 31/12/1995 |
Formazione di Eric M. Gordon
| University of Wisconsin | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 9 |
|---|---|
Skyline Management LLC
Skyline Management LLC Investment ManagersFinance Skyline Management LLC (Skyline Management) is a venture capital firm founded in 1997 by John Gordon Freund. The firm is headquartered in Palo Alto, California. | Finance |
Limulus Management Co. LLC
 Limulus Management Co. LLC Investment ManagersFinance Limulus Management Co. LLC is a venture capital firm founded by Lawrence Miller and Paul Howard in 1999. It is headquartered in Newton, Massachusetts. | Finance |
| Squibb Corp. | Health Technology |
Affymax Research Institute
Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | Commercial Services |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Targanta Therapeutics Corp.
Targanta Therapeutics Corp. BiotechnologyHealth Technology Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
Arixa Pharmaceuticals, Inc.
Arixa Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arixa Pharmaceuticals, Inc. engages in the development of oral antibiotics for resistant gram-negative infections. The company was founded by Eric Gordon, John Gordon Freund, and Joaquim Trias in 2016 and is headquartered in Palo Alto, CA. | Health Technology |
- Borsa valori
- Insiders
- Eric M. Gordon
